Enspryng
Preclinical
AmgenEnspryng is one of 21 therapeutic programs targeting Neuromyelitis Optica. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
21 competitors in Neuromyelitis Optica
#DrugCompanyPhaseTrials
1Soliris
AstraZenecaApproved
Cellcept
RocheApproved
UPLIZNA
HHorizon Therapeutics Ireland DAC
Approved
Imuran
LLegacy Health System
Approved
Novantrone
EMD SeronoApproved
Rayos
RRoxane Laboratories
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Brukinsa
BBeOne Medicines
Approved
Mesnex
BBaxter Healthcare Corporation
Approved
Darzalex
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Enspryng. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company